Hyperinsulinemic hypoglycemia is the most common cause of severe, persistent neonatal hypoglycemia. The treatment of hyperinsulinemic hypoglycemia that is unresponsive to diazoxide is subtotal ...

Acute GVHD (aGVHD) is a major cause of morbidity and mortality in hematopoietic allograft recipients. The best therapy for patients failing to respond, or not tolerating, systemic glucocorticoids ...

Sirolimus-eluting stents and paclitaxel-eluting stents, as compared with bare-metal stents, reduce the risk of restenosis. It is unclear whether there are differences in safety and efficacy between ...

Please provide your email address to receive an email when new articles are posted on . Four of six patients who used sirolimus had positive responses and discontinued systemic corticosteroids. Three ...

Background: Sirolimus-eluting stents have recently been shown to reduce the risk of restenosis among patients who undergo percutaneous coronary intervention (PCI). Given that sirolimus-eluting stents ...

Elevation of liver function tests (LFTs) has been noted in patients treated with sirolimus. However, in the United States [1] and global phase 3 trials, [2] elevation of LFTs, specifically of AST ...

For the first time, a product is available specifically for use in patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors. The product is an ...

Please provide your email address to receive an email when new articles are posted on . A novel sirolimus liposomal formulation was beneficial for the treatment of signs and symptoms of moderate to ...

Newark, May 22, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 250 million in 2023 global sirolimus market will reach USD 370.06 million in 2033. Sirolimus is also known as ...

LONDON, England—While it’s not clear sirolimus-based devices will ever overtake the old workhorse paclitaxel, data from several studies presented here at the 2025 Charing Cross International Symposium ...